CliffBio
small molecule

NEXICLON XR

CLONIDINE

Loss of exclusivitySeptember 2031latest FDA-listed patent expiry
CompanyRosemont Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameNEXICLON XR
Active ingredientCLONIDINE
StrengthEQ 0.26MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2009
Marketing statusDISCN

Listed patents

PatentExpiresType
8623409September 2031product
8337890April 2027product

More from Rosemont Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found